Work

The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: final analysis including overall survival

Year: 2024

Type: article

Abstract: Not available.

Source: Haematologica

DOI: 10.3324/haematol.2024.285043

Authors: Alexey V. Danilov, Ian W. Flinn, Matthew S. Davids, Beth Gregory, Ohad Bentur, David Sidransky, Jennifer R. Brown

Institutions: City Of Hope National Medical Center, Tennessee Oncology, Dana-Farber Cancer Institute, Johns Hopkins University, Dana-Farber/Harvard Cancer Center

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,157

Funder: National Cancer Institute

Award: G1547207268

OpenAlex ID: W4399177125

FWCI: 1.885

Cites: 11

Cited by: 8

Related to: 10